Stocks / Pharmaceuticals

NKTRPharmaceuticals

Nektar Therapeutics
$68.501d +2.2%5d -2.9%settled close · 2026-09-17
Mkt cap $2.1B (3/25)β 1.1452w $56–98Shares 28.7MInd. Pharmaceutical PreparationsNasdaq since 1994Emp. 63HQ San Francisco, CAnektar.com
The tape, with the calls on it

Who said what, and what NKTR did next

Every dot is a day someone on the record made a call. Hover one to see who. We are not scoring them — the point is that you can see it and judge for yourself.

bullish bearish both sides
Who’s talkingIdea Scout · free

Who’s talking about NKTR

2 longlatest 2026-06-10
DateVoiceStanceVenueThesis
2026-06-10Adam MayPhysician & Biotech InvestorBullishYet Another Value PodcastAlopecia areata data showed deepening responses with longer treatment confirming a legitimate signal, the…
2026-03-23Adam MayPhysician & Biotech InvestorBullishYet Another Value PodcastRezpeg's eczema efficacy is materially understated due to Eli Lilly's botched data analysis and a…
Idea Scout tracks who’s talking across television, podcasts, and interviews — every stance dated to the appearance it came from. Sign up free →
Earnings

Next report: 4 Nov 2026 after the close

Confirmed date · consensus EPS -2.17. Reactions below are the next settled session over the prior close.
ReportWhenEPS actual vs est.Reaction
13 Aug 2026after the close-1.23 vs -2.02-2.7%
The options tape

Notable options days

Sessions in the last 120 where NKTR’s settled options volume ran ≥ 2× its trailing 20-session baseline, or delta-dollar flow ran ≥ 2.5× — 10 of 120 sessions qualified.

The qualifying dates are the free record. Close, flow, call/LEAPS mix and the 20-session outcome — for every session below — are Brief subscriber content.
DateCloseRVOL Δ$ flow ($M)Call % LEAPS %+20 sess.
2026-09-17
2026-09-15
2026-08-14
2026-08-13
2026-08-07
2026-08-05
2026-07-07
2026-07-06
2026-06-30
2026-06-22
+20 sess. = raw price change over the following 20 sessions — not market-adjusted; the tape tells you where to look, not what happens next.
Today’s tape on NKTR is in this morning’s Brief. Get The Brief — $20/mo →